newark-california
(4)
Protagonist Therapeutics
Protagonist Therapeutics is a Newark, California clinical-stage biopharmaceutical company that turns peptides - short chains of amino acids long dismissed as too fragile to be drugs - into stable, often orally available medicines. Its proprietary peptide discovery and engineering platform powers a pipeline spanning hematology, inflammation/immunology and metabolic disease, anchored by rusfertide (a hepcidin mimetic for polycythemia vera under FDA Priority Review) and icotrokinra, an oral IL-23 receptor blocker partnered with Johnson & Johnson that reached the U.S. market in 2026. Publicly traded on Nasdaq as PTGX, the company pairs internal discovery with high-value pharma partnerships.
Lucid Motors
Lucid Motors is an American luxury electric-vehicle maker based in Newark, California, building the longest-range production EVs in the world. Its in-house powertrain and battery engineering deliver class-leading efficiency in the Lucid Air sedan and the Gravity SUV, backed heavily by Saudi Arabia's Public Investment Fund.
Marc Winterhoff
Marc Winterhoff is the interim Chief Executive Officer of Lucid Motors, the Newark, California luxury EV maker behind the Air sedan and Gravity SUV. A German-trained electrical engineer who spent decades advising automakers at Roland Berger and Arthur D. Little, he joined Lucid as COO in December 2023 and was elevated to interim CEO in February 2025 after founder Peter Rawlinson stepped aside. He has steered the company through a fragile stretch: stretching the cash runway into 2027, deepening the PIF and Uber partnerships, and prepping a robotaxi-ready Midsize platform. In April 2026 Lucid named Schindler veteran Silvio Napoli as permanent CEO; Winterhoff will return to the COO role.
Dinesh V. Patel
Dinesh V. Patel, Ph.D. is the President and CEO of Protagonist Therapeutics (NASDAQ: PTGX), a Newark, California-based biopharmaceutical company he has led since December 2008. With over 38 years spanning medicinal chemistry, drug discovery, venture capital co-founding, and three CEO stints, Patel has guided Protagonist from a peptide-platform startup to a company with its first FDA-approved drug - ICOTYDE (icotrokinra), approved March 2026 as the world's first targeted oral peptide for moderate-to-severe plaque psoriasis, partnered with Johnson & Johnson.